Skip to main content
. 2013 May 1;140(9):1946–1957. doi: 10.1242/dev.089920

Fig. 2.

Fig. 2.

Cardiomyocyte-restricted ablation of Fkbp1a using H1-Ncx-cre transgenic mice. (A) Dual immunofluorescence analyses confirm the genetic ablation of Fkbp1a in developing myocardium at E12.5. Representative confocal images of heart sections co-stained with Alexa Fluor 647-conjugated anti-Fkbp1a antibody (red) and Alexa Fluor 488-conjugated anti-myosin heavy chain antibody (MF-20; green). There is a significant reduction in Fkbp1a in Fkbp1aflox/-:H1-Ncx-cre myocardium. The boxed regions of the merge are enlarged to the right. (B) Western blot confirms the efficient removal of Fkbp1a in Fkbp1aflox/-:H1-Ncx-cre heart. (C) Morphological and histological analysis of Fkbp1aflox/-:H1-Ncx-cre and control hearts at E14.5. RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle.